NOVO NORDISK
Wed, 05 May 2021 05:46:00 -0400
Wed, 05 May 2021 05:46:00 -0400
5 May 2021
PROFIT AND LOSS |
Q1 2021 | Q1 2020 |
Growth as reported | Growth at CER* |
USD million |
|
|
|
|
Net sales | 5,479 | 4,997 | 0% | 7% |
Operating profit | 2,428 | 2,405 | (8%) | 3% |
|
|
|
|
|
Net profit | 2,046 | 1,755 | 6% | N/A |
Diluted earnings per share (in USD) | 0.88 | 0.74 | 8% | N/A |
* CER: Constant exchange rates (average 2020).
Lars Fruergaard Jørgensen, president and CEO: "We are very encouraged with the sales growth in the first three months of 2021. Sales growth was driven by all therapy areas and across geographical areas within International Operations as well as North America Operations where growth has accelerated in the US. We were also pleased to announce plans to develop oral semaglutide as a convenient and effective treatment option for people with obesity, complementing our injectable obesity medications. The solid financial performance in the first three months of 2021 has enabled us to raise our outlook range for the full year."
On 5 May 2021 at 13.00 CEST, corresponding to 7.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.
**For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.0 = DKK 6.16973